Ashland Inc. heads into its Q3 earnings call with options traders positioned more bullishly than at any point in the recent past — a sharp contrast to the elevated short interest that has defined the stock all year.
The options signal is the most striking feature of the current setup. The put/call ratio has collapsed to 0.10, nearly 1.5 standard deviations below its 20-day average of 0.22, and is now approaching the 52-week low of 0.07. That means call volume is running at roughly ten times put volume — unusually aggressive bullish hedging for a specialty chemicals name that rarely attracts this kind of directional positioning. The move looks deliberate rather than mechanical, with the PCR dropping sharply from the 0.28 range where it sat through most of July to its current level over just the past week.
Short interest tells a less straightforward story. Bears remain a real presence: 12.1% of the free float is sold short, a level that ranks in just the 3rd percentile on ORTEX's short score rankings — meaning this stock carries more short pressure than 97% of the universe. Yet the shorts have been quietly covering. Shares sold short declined roughly 800,000 over the past month, with a further 2% drop in the last session alone. The borrow market is relaxed: cost-to-borrow runs at just 0.56%, and availability is ample at 243% of short interest, well off the 52-week tightest levels. Covering pressure, not a squeeze, is the story.
The analyst setup has improved materially since the last print. JP Morgan lifted its target to $75 — up from $65 — earlier this month, maintaining an Overweight. UBS also raised its target to $72 in June. Both moves came after April's sharper-than-expected reaction, when the stock fell 6.6% on the day and a further 4.2% over the following five sessions. The consensus mean target of $71.27 sits modestly above Ashland's current price of $68.01, implying a Street that sees upside but not a re-rating — an "execution creditors" posture rather than a growth call. Wells Fargo remains a dissenting voice, holding an Equal-Weight with a $50 target, anchored on concerns that a recovery in specialty chemicals volumes remains sluggish. Valuation is undemanding: the stock trades at roughly 10.5x EV/EBITDA, little changed over the past month, and 16.8x trailing earnings.
Institutional ownership adds an interesting layer. BlackRock added nearly 1.35 million shares in Q2, lifting its stake to 12.3% of shares outstanding. Standard Investments, a less familiar name, holds 8.9% after adding 1.47 million shares earlier this year. Franklin Resources added over 1.1 million shares in the same period. That accumulation contrasts with the residual short positioning — a clear disagreement between longer-horizon holders who have been buying and shorter-term traders who have been reluctant to fully exit.
The print tests whether Ashland can post a result that justifies the recovery from the April sell-off, quiets the remaining shorts, and gives those accumulating institutional holders the volume and margin evidence they need to hold their positions.
See the live data behind this article on ORTEX.
Open ASH on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
